DİKİLİTAŞ, M. 2020. Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?. JOURNAL OF GASTROINTESTINAL CANCER , vol.51, no.4 , 1193-1196.

DİKİLİTAŞ, M., (2020). Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?. JOURNAL OF GASTROINTESTINAL CANCER , vol.51, no.4, 1193-1196.

DİKİLİTAŞ, MUSTAFA. "Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?," JOURNAL OF GASTROINTESTINAL CANCER , vol.51, no.4, 1193-1196, 2020

DİKİLİTAŞ, MUSTAFA. "Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?." JOURNAL OF GASTROINTESTINAL CANCER , vol.51, no.4, pp.1193-1196, 2020

DİKİLİTAŞ, M. (2020) . "Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?." JOURNAL OF GASTROINTESTINAL CANCER , vol.51, no.4, pp.1193-1196.

@article{article, author={MUSTAFA DİKİLİTAŞ}, title={Why Adjuvant and Neoadjuvant Therapy Failed in HCC. Can the New Immunotherapy Be Expected to Be Better?}, journal={JOURNAL OF GASTROINTESTINAL CANCER}, year=2020, pages={1193-1196} }